Publications

L'Espérance K, Lin K, Lichtensztajn D, Christoph Soerensen SJ, Gulati S, Deng Z, Leppert JT, Oh DY, Sakoda LC, Washington SL, Meng MV, Chan JM, Langston ME, Cheng I, Chung BI, Graff RE. Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019. Lancet regional health. Americas. 2026. PMID: 41800233

Armstrong AJ, Morris MJ, Abida W, Aggarwal RR, Antonarakis ES, Attard G, Beltran H, Bryce A, Carducci MA, Cheng HH, Chen DL, Chi KN, Childs DS, Dahut W, Emmett L, Fizazi K, Gafita A, George DJ, Hermann K, Hofman MS, Hope T, Hussain M, Kelly WK, Kessler E, Kuo PH, Lang J, Liu G, Marshall CH, Morgans AK, McKay RR, Nanus D, Nelson P, Paller C, Reichert ZR, Ryan CJ, Sartor AO, Schöder H, Schwartz LH, Sharifi N, Stadler WM, Stein M, Sternberg CN, Szmulewitz RZ, Tagawa ST, Sokolova AO, Wyatt AW, Yamoah K, Yu EY, Halabi S, Scher HI, PCWG4 Writing Group. Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41744290

Ma RK, Tsai PY, Farghli AR, Shumway A, Kanke M, Gordan JD, Gujral TS, Vakili K, Nukaya M, Noetzli L, Ronnekleiv-Kelly S, Broom W, Barrow J, Sethupathy P. Correction: DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma. PLoS genetics. 2026. PMID: 41746900

Rugo HS. Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer. The New England journal of medicine. 2026. PMID: 41740036

Shah NJ, Sura S, Shinde R, Dai W, Wentworth C, Conkling P, Bupathi M, Vickery D, Perini R, Motzer RJ. Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study. Urologic oncology. 2026. PMID: 41760529

Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R, Smith TJ, Trapani D, Woodard AB, Cigler T. WBC Growth Factors: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41740078

Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS. Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer. Breast (Edinburgh, Scotland). 2026. PMID: 41830752

Wood WA, Kumar SK, Semmel E, James S, Schroeder MA, Chung DJ, Rosenberg AS, Zonder JA, Rubinstein SM, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson LD, Derkach A, Geyer S, Usmani SZ. Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma. Blood advances. 2026. PMID: 41734388

Raizenne BL, Koshkin VS, Zhu A, Ben-David R, Dufault SM, Eraky A, Friedlander TW, Hong JC, Wong AC, Chou J, Chu C, Mar N, Ma TM, Sfakianos JP, Porten S, Seyedin SN. Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer. Clinical genitourinary cancer. 2026. PMID: 41864146

Kumar J, Jensen A, Lu R, Khanna V, Stehr H, Spinner M, Fernandez-Pol S, Greenberg PL, Tan B. Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype. Journal of hematopathology. 2026. PMID: 41721060

Bocobo A, Whitman J, Keenan BP, Koser KL, Kidder WA, Piawah S, Van Loon K, Behr SC, Kolli KP, Chen X, Onodera C, Pande M, Pollak M, Wang R, Babdor J, Spitzer MH, Zhang L, Fong L, Atreya CE. Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer. Clinical colorectal cancer. 2026. PMID: 41826077

Kodali PB, Pednekar MS, Gupta PC, Quah ACK, Fong G?, Bialous SA, Vijayaraghavan M. Cessation outcomes and healthcare provider advice to quit among tobacco users: A cross-sectional analysis of the 2018-2019 Tobacco Control Policy (TCP) India survey. Tobacco induced diseases. 2026. PMID: 41716892

Kelley RK, Lee Y, Conway J, Kurland JF, McCoon P. T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41359405

Emamekhoo H, Riaz IB, Martin DB, Gabriel PE, Shah NJ, Bruckner L, Arafat W, Fu P, Freimuth RR, Liebovitz DM, Stillman RC, Stapp RT, Perkins RM, Sugalski J, Heinrichs T, Tevaarwerk AJ. Deriving wisdom from data: The value and continued rationale for structured data in the era of artificial intelligence-driven oncology care. Cancer. 2026. PMID: 41701629

Zhu X, Alvarez EA, Umetsu SE, Chapman JS, Chen LM, Ueda S, Henderson S, Nguyen P, Calabrese S, Russell J, Aguilar J, Smith SA, Shah N, Feeney L, Van Ziffle J, Turski ML, Ko AH, Munster PN, Ashworth A, Collisson EA, Aggarwal RR. Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41686845

Liu CH, Chen YL, Ai W, Ni HC, Lai MC. The impact of autism on the relations between social anxiety, camouflaging, and depression in Taiwanese adolescents. Child and adolescent psychiatry and mental health. 2026. PMID: 41689079

Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R. Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial. Research square. 2026. PMID: 41727611

Vieira Dos Santos J, Melnekoff DT, Aleman A, Mouhieddine TH, Montes de Oca R, Wang F, Rajeeve S, Bhalla S, Van Oekelen O, Upadhyaya B, Ghodke-Puranik Y, Leshchenko V, Kim-Schulze S, Rahman A, Afik S, Lewinsky H, Plaks V, Thibaud S, Cho HJ, Richter J, Rodriguez C, Sanchez L, Rossi A, Richard S, Chari A, Madduri D, Jagannath S, Parekh S, Laganà A. Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression. Blood advances. 2026. PMID: 41191534

Choucair A, Zdunek A, Liao M, Bodei L, Deandreis D, Das J, Barbe R, Bergsland E, Geyer S, Bidault F, Garcia G, Yeh R, Balleyguier C, Lassau N, Dercle L, Ammari S. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management. Insights into imaging. 2026. PMID: 41661399

Manabe T, Bergo HC, Li Q, Wang TS, Severson P, Miller N, Lee C, Yay Donderici E, Zhang N, Wu W, Chou YT, Kerr DL, Allegakoen P, Grandinetti KB, Soroceanu L, Pelham RJ, Martin ES, Murphy EA, Khanna V, Neal JW, Chen CT, Kato S, Williams R, Bivona TG. Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies. Nature communications. 2026. PMID: 41654519